The PE Ratio as of November 2024 (TTM) for ALX Oncology Holdings Inc. (ALXO) is -0.47

According to ALX Oncology Holdings Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.47. This represents a change of -82.34% compared to the average of -2.66 of the last 4 quarters.

ALX Oncology Holdings Inc. (ALXO) Historical PE Ratio (quarterly & annually)

How has ALXO PE Ratio performed in the past?

The mean historical PE Ratio of ALX Oncology Holdings Inc. over the last ten years is -33.00. The current -0.47 PE Ratio has changed 42.42% with respect to the historical average. Over the past ten years (40 quarters), ALXO's PE Ratio was at its highest in in the September 2024 quarter at -0.78. The PE Ratio was at its lowest in in the September 2019 quarter at -54.09.

ALX Oncology Holdings Inc. (ALXO) PE Ratio by Quarter and Year

Discovering the peaks and valleys of ALX Oncology Holdings Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

ALX Oncology Holdings Inc. (ALXO) Average PE Ratio

How has ALXO PE Ratio performed in the past?

The current PE Ratio of ALX Oncology Holdings Inc. (ALXO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

ALX Oncology Holdings Inc. (ALXO) PE Ratio vs. Peers

How is ALXO’s PE Ratio compared to its peers?

ALX Oncology Holdings Inc.’s PE Ratio is greater than Cabaletta Bio, Inc. (-0.88), less than Viracta Therapeutics, Inc. (-0.15), greater than EyePoint Pharmaceuticals, Inc. (-4.71), greater than Biomea Fusion, Inc. (-1.62), greater than Crinetics Pharmaceuticals, Inc. (-16.16), greater than Immatics N.V. (-12.59), greater than BioAtla, Inc. (-0.93), greater than Aerovate Therapeutics, Inc. (-0.91), greater than Dyne Therapeutics, Inc. (-10.17), greater than Edgewise Therapeutics, Inc. (-24.30), greater than Cullinan Oncology, Inc. (-5.10), greater than Stoke Therapeutics, Inc. (-6.11), greater than Mineralys Therapeutics, Inc. (-4.06), greater than Century Therapeutics, Inc. (-0.79), greater than C4 Therapeutics, Inc. (-2.80), less than TCR2 Therapeutics Inc. (-0.38), greater than Revolution Medicines, Inc. (-16.70), greater than Black Diamond Therapeutics, Inc. (-1.96), less than Atreca, Inc. (-0.06), less than Passage Bio, Inc. (-0.45),

Build a custom stock screener for ALX Oncology Holdings Inc. (ALXO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ALX Oncology Holdings Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

ALX Oncology Holdings Inc. (ALXO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like ALX Oncology Holdings Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.